ACOR - Acorda Therapeutics, Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Acorda to regain global commercialization rights to FAMPYRA by Jan 2025
• Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M
• Acorda Therapeutics GAAP EPS of -$7.55, revenue of $29.68M
• Acorda Therapeutics regains compliance with Nasdaq's minimum bid price rule
• Acorda Therapeutics launches 1-for-20 reverse stock split
• Acorda Therapeutics GAAP EPS of -$0.69 beats by $0.42, revenue of $22.25M misses by $8.76M
• Acorda Therapeutics Q1 Earnings Preview
• Acorda Therapeutics down 8%, makes $6.2M interest payment in cash
• Acorda Therapeutics and Hangzhou Chance Pharmaceuticals join forces to introduce Parkinson's disease therapy in China; shares surge by 7%
• Acorda stock dips as Q4 revenue slumps ~15%
• Acorda Therapeutics GAAP EPS of $0.57, revenue of $31.47M
• Notable earnings before Thursday's open
• Acorda Therapeutics receives Nasdaq extension to meet minimum bid price requirement
• Acorda strikes new global supply deal with Catalent for its inhalation powder Inbrija
• Acorda projects positive adj. EBITDA in revised 2022 guidance
• Acorda Therapeutics gets Nasdaq delisting notice, plans to appeal decision
• Acorda Therapeutics GAAP EPS of -$0.57, revenue of $33.51M
• Trex Company, The Goodyear Tire & Rubber, Varonis Systems among premarket losers' pack
• Acorda gains on plans to become cashflow positive in 2023
• Acorda wins $16.5M in Ampyra arbitration case with Alkermes